Aytu Biopharma Inc AYTU
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2017-10-20 |
| Shares Out. | 10,730,000 |
| Website | aytubio.com/ ↗ |
| Phone | 13026365400 |
| Employees | 83 |
| Revenue | $12.4M |
| Gross Profit | $7.6M |
| Net Income | -$5.6M |
| Free Cash Flow | $1.6M |
| Total Assets | $111.7M |
| Total Liabilities | $76.5M |
| Equity | $35.1M |
About Aytu Biopharma Inc
Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline, including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates one business segment consisting of various prescription pharmaceutical products sold through third parties.
Aytu Biopharma Inc is a publicly traded company under the ticker symbol AYTU on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)